Global Feature
Patent Reform and the Pharmaceutical Industry: From First-to-File to Post-Grant Review and Beyond
Courtenay C. Brinckerhoff, partner of Foley & Lardner LLP and vice-chair of the firm's chemical, biotechnology and pharmaceutical practice. The author discusses the major changes in US patent laws as a result of the recently signed patent-reform law and the implications for pharmaceutical companies.

APIs Technical Perspectives: Antibody Drug Conjugates A podcast moderated by Patricia Van Arnum, executive editor of Pharmaceutical Technology and editor of Sourcing and Management.
Grant E. Boldt, PhD, director of European business development for SAFC, discusses manufacturing considerations in producing antibody drug conjugates.


Outsourcing
Biosimilars' Technology Needs
Eric Langer, president of BioPlan Associates
Biosimilar manufacturers need better expression systems and analytical tools to compete.

CSR and Sustainability Forum
Pharmaceutical Technology’s dedicated editorial coverage on the developments in corporate social responsibility (CSR) and sustainability from the bio/pharmaceutical industry, other business sectors, and public and private organizations. This month, we feature articles on pharmaceutical companies’ sustainability objectives and green-manufacturing projects, the World Health Organization’s progress report on combating HIV/AIDS, and a roundup of CSR and sustainability news.
Pharmaceutical Companies Target Green Manufacturing Patricia Van Arnum, executive editor of Pharmaceutical Technology and editor of Sourcing and Management.
A roundup of pharmaceutical companies' sustainability objectives and key green manufacturing projects.

World Health Organization Issues Progress Report on Combating HIV/AIDS
Patricia Van Arnum, senior editor of Pharmaceutical Technology, and editor of Sourcing and Management
International efforts, including improving access to medicines, have contributed to stemming the rise of HIV/AIDS in the developing world.

CSR and Sustainability in the News
A roundup of developments in corporate social responsibility and sustainability from the bio/pharmaceutical industry, its suppliers, and other public and private organizations.

|